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ABSTRACT. Shared needle and syringe use among injection drug
users continues to be a major mode of transmission of HIV. Needle
and syringe exchange (NSE) may be a viable strategy to reduce the
transmission of the virus; yet the difficulty in measuring the actual effi-
cacy of NSE has limited attempts to evaluate the cost-effectiveness of
the intervention. Using data specific to the Lower East Side Harm
Reduction Center in New York City, we assessed the cost-effectiveness
of NSE over a range of conservative estimates of efficacy, obtained
from both longitudinal and small-area studies. A decision-analysis
model was created to compare the outcomes and costs associated with
NSE. Model inputs included the cost of living with HIV and the sero-
prevalence of HIV among injection drug users in New York City. This
analysis was conducted from both the government and societal
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perspectives. Tested over a range of conservative parameter estimates,
NSE appears to save money and lives. The NSE program we evaluated
cost $502 per client and produced a gain of 0.01 quality adjusted life
years per client. It also reduced HIV treatment costs by $325,000
per case of HIV averted, and averted 4–7 HIV infections per 1000
clients, producing a net cost savings.
KEYWORDS. Cost-effectiveness analysis, harm reduction, HIV
Prevention, needle exchange, needle and syringe exchange, NEP,
NSE, NSP, SEP, syringe exchange
BACKGROUND
More than 25 years after the first cases were reported, HIV=AIDS
continues to be a serious health threat in New York City. New York
City has the largest AIDS case rate in the country, and HIV=AIDS is
the city’s third leading cause of mortality for people below the age
of 65 (New York City Department of Health and Mental Health
Hygiene [NYCDOHMH], 2006a). The New York City Department
of Health and Mental Health Hygiene (2006a) estimates the total
number of people living with HIV=AIDS in New York City to be
between 103,290 and 143,402 people, as of 2002.
Injection drug use continues to be a major mode of transmission
in New York City. Seroprevalence among the city’s injection drug
users (IDUs)—a population of 162,500 individuals—is estimated at
approximately 13.5% (NYCDOHMH, 2004). Between January 1
and March 31, 2005, 16.5% of persons with a new AIDS diagnoses
reported a history of injection drug use (NYCDOHMH, 2004,
2006b).
Needle and syringe exchange (NSE) is a viable strategy to reduce
the spread of HIV among IDUs (Des Jarlais et al., 1996, 2005;
Hagan, Des Jarlais, Purchase, Reid, & Friedman, 1995; Hurley,
Jolley, & Kaldor, 1997; Kaplan & O’keefe, 1993; Laufer, 2001).
Needle and syringe exchange programs provide channels for IDUs
to exchange used syringes and needles for new, sterile ones, effectively
reducing the average circulation time of used, contaminated syringes
and needles and lowering the probability of their reuse (Laufer).
While NSE is intuitively effective, ethics limit study designs to
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mathematical models, tagged syringe tracking studies, temporal
designs, retrospective analyses, and small-area analysis. Needle and
syringe exchange is legal in New York State and is regulated by the
New York State Department of Health. In New York City there
are currently nine legal NSE programs in operation (Harm Reduction
Coalition, 2006).
Cost-effectiveness analysis is an important tool for estimating the
efficiency of competing alternative medical and health interventions.
By providing information on the costs and health benefits of one
intervention relative to another, it becomes possible to ascertain
how limited funds can be spent to maximize the total number of lives
saved and health gained. This study will assess the cost and effective-
ness of NSE as an intervention to prevent the transmission of HIV
among its clients (relative to no intervention), using cases of HIV
averted, as well as the quality adjusted life years (QALYs) gained
as outcome measures. A QALY is a year of life lived in a state of
perfect health. The QALY simultaneously captures both morbidity
and mortality in a single metric (Weinstein, Siegel, Gold, Kamlet,
& Russell, 1996).
The objective of this study is to examine whether NSE pro-
grams merit further investment and expansion based on their
cost-effectiveness. Because previous studies have found that NSE
programs are cost-saving, we biased model inputs against the con-
clusion that NSE programs will save money, lives, and QALYs
(Gold, Gafni, Nelligan, & Millson, 1997; Laufer, 2001). This
approach minimizes uncertainty associated with model outputs.
We then tested the model inputs across a broad range of plausible
NSE efficacy values in order to ascertain the extent to which NSE
programs are cost-saving at the lowest plausible estimates of pro-
gram efficacy.
This study was commissioned by the Lower East Side Harm
Reduction Center (LESHRC), which runs one of the nine NSE pro-
grams in operation in New York City. Cost-effectiveness analysis is
an important tool for estimating the efficiency of competing alterna-
tive medical and health interventions. This study relied on data
from the medical literature and anonymous, aggregated administrat-
ive data from the Lower East Side Harm Reduction Center.
Because no personal information of any individual was accessed
or used for this study, Institutional Review Board approval was
not required.
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METHODS
This analysis was conducted from the government perspective
using constant 2005 dollars. We constructed a deterministic decision-
analysis model that compared two strategies: participation in NSE
(i.e., an IDU chooses to exchange used needles and syringes for
new, sterile equipment) versus no participation (i.e., an IDU does
not utilize the needles and syringes offered). We excluded costs asso-
ciated with Hepatitis B and C infection, the transmission of which
may also be reduced by NSE, biasing the study against the conclusion
that needle exchange programs are not cost-effective. Future costs
and QALYs were discounted at a rate of 3% (Weinstein, Siegel, Gold,
Kamlet, & Russell, 1996).
Decision-Analysis Model
A decision-analysis model was created using TreeAge Pro 6.0 for
Microsoft Windows. All assumptions for the model are listed in
Table 1. The model is designed to obtain the probabilistic, weighted
average cost and effectiveness value of each pathway (NSE or no
NSE). The cost, probability of illness, and life expectancy inputs
are listed in Table 2. While the NSE pathway is associated with a
lower probability of contracting HIV (with its associated costs,
changes in health-related quality of life, and longevity), subjects in
this arm also incur the costs of NSE. The no-NSE pathway is
TABLE 1. Assumptions Used in Deriving Parameter Estimates and Justification
Assumption Justification
HIV negative IDUs have a life expectancy
similar to populations of the same
sociodemographic characteristics
No other comparator was readily available,
and the baseline life-expectancy value
exerts little or no effect on the estimated
improvements in life expectancy with SEP
Life expectancy of HIV positive is the same
for both NSE and non-NSE pathways
While NSE may improve HIV-positive
persons’ access to care via medical
referrals, this assumption was made to
ensure that the results were as
conservative as possible
HIV-positive LESHRC clients will incur costs
similar to HIV-positive Medicaid patients
LESHRC survey data reports 75% of all
clients to be enrolled in Medicaid
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associated with a higher probability of contracting HIV, but no NSE
program costs.
Probabilities
The reduced probability of HIV transmission through injection
drug use associated with NSE was calculated using the seroprevalence
of HIV among IDUs and the reduction in seroprevalence associated
with NSE programs. The most recent report on HIV prevalence by
the NYCDOMH (2004) estimates HIV seroprevalence among IDUs
in New York City to be 13.5% in 2002.
To estimate the efficacy of NSE, we employed a range of possible
values, varying from no efficacy to 5.8% effective at reducing the
seroprevalence of HIV. The two best estimates of the reduction in
seroprevalence associated with NSEs came from a small-area analysis
conducted by Hurley et al. (1997) just before the advent of protease
inhibitors, and a prospective study with a before=after control con-
ducted by De Jarlais et al. (2005). The small-area analysis adjusted
for relevant covariates and estimated the impact of NSEs on the over-
all seroprevalence within a geographic region and found that NSEs
TABLE 2. Selected Parameters Included in the Decision-Analysis Model








among IDUs in New York
City
0.135 0.20 0.07 (New York City, 2004)
Average annual Medicaid
HIV cost per enrollee,
2005 dollars
$34,651.65 – – (New York State,
2001)
NSE annual cost per client,
2005 dollars
$501.54 – – LESHRC
Life expectancy of HIV-
negative IDU, in Quality
Adjusted Life Years
(QALYs)
20.91 – – (Paltiel et al., 2005)
Life expectancy of HIV-
positive IDU, in QALYs
18.34 – – (Paltiel et al., 2005)
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reduced seroprevalence by 5.8%. The latter longitudinal study found
that NSE was associated with a 3.3% reduction in HIV seropreva-
lence among IDUs in New York City. This study, which spanned
from 1990–2002, did not control for the adoption of protease inhibi-
tors in the mid-1990s, nor did it sufficiently control for the effect of
the prevention efforts that often accompany NSE, such as condom
distribution, in the IDU population under study.
Given the limitations of these studies, and a desire to derive a con-
servative estimate of NSE efficacy, we arbitrarily chose to halve the
value obtained in the Hurley et al. (1997) cross-sectional analysis,
yielding a value of 2.9%. This value is lower than the majority of pub-
lished NSE efficacy values (Des Jarlais et al., 1996, 2005; Hagan et al.,
1995; Hurley et al., 1997; Kaplan & O’keefe, 1993; Laufer, 2001). We
created two parameters, s, the seroprevalence, and r, the reduction in
s due to NSE. Using these parameters, we set the probability of HIV
transmission for IDUs who do not participate in NSE to be s, and the
probability of transmission for IDUs who do participate in NSE to
be s=(1þ r).
Cost
The costs associated with NSE were obtained for the year 2005
from LESHRC and are listed in Table 2. To ensure that the
incremental cost-effectiveness ratio was as conservative as possible,
we included both variable and fixed costs, without depreciating fixed
assets. Fixed costs constitute 40% of the LESHRC’s budget. Our
total estimated costs were therefore substantially higher than pre-
vious estimates of costs associated with similar NSEs (Laufer, 2001).
In 2005 LESHRC had 1,484 clients participating in its NSE pro-
gram. The clients were 72.37% male, 27.56% female, and 0.07% trans-
gender. Seventy-four percent were between the ages 20 and 50, 2%
were below the age of 20, and 24% were over the age 50. Approxi-
mately 75% were enrolled in Medicaid. Cost structures for other
programs were assumed to be similar.
The costs associated with HIV infection were calculated for life,
using life expectancy estimates for an HIV-positive IDU on treat-
ment. As the majority of LESHRC clients are enrolled in Medicaid,
the costs associated with HIV infection were obtained from the New
York State Department of Health’s (2001) 2002 reported annual
Medicaid expenditures per enrollee with HIV=AIDS. The 2002
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average Medicaid costs for an enrollee living with HIV=AIDS
included inpatient care, ambulatory and emergency room care,
freestanding clinic costs, physician costs, pharmacy costs, treatment
costs (including antiretrovirals and protease inhibitors), institutional
long-term care, home health care, personal care, and other costs
(New York State Department of Health). We assumed that the subset
of HIV-positive IDUs was mostly receiving Medicaid funding, or
funding from other public programs with similar costs.
Life Expectancy
The average life expectancies for both a HIV-negative and a HIV-
positive IDU were obtained from a recent study by Paltiel et al.
(2005). Using a computer-simulation model, the researchers esti-
mated mean-quality adjusted survival among high-risk populations
in the United States and among HIV-infected members of high-risk
populations. These baseline parameter estimates are listed in Table 2.
Sensitivity Analyses
Variables r and s were tested for their influence on the model; base-
line estimates for these parameters and a range of possible values for
each estimate are listed in Table 2. Both variables were tested by uni-
variate analysis, as well as bivariate analysis.
RESULTS
The cost and effectiveness of each strategy estimated by the
decision-analysis model are listed in Table 3. The NSE was the domi-
nant strategy, as it was found to be both cost saving and life saving
when r was set to the high value, 0.058. For year 2005 the program
resulted in an estimated savings of about $3,000 per client and a gain
of 0.02 QALYs due to reduced transmission of HIV, relative to if the
program was not in operation. When the baseline value of 0.029 was
used, the program resulted in an estimated savings of approximately
$1,300 per client, a gain of 0.01 QALYs.
Using baseline values, NSE results in a total savings of $1.3 million
per 1,000 clients, which is the cost associated with approximately four
cases of HIV averted, at a cost of $502 per client, or $125,000 per case
of HIV averted.
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The model was tested for the influence of parameters s (HIV sero-
prevalence among IDUs) and r (the reduction in HIV seroprevalence
associated with NSE). The result of a one-way analysis on r is shown
in Figure 1. Although r is the most important parameter used in this
study, it is also the least reliable. A one-way analysis from 0 (NSE is
not effective) to 0.058 (the high value) shows the NSE to be cost sav-
ing if it is associated with a reduction in HIV seroprevalence greater
than 0.008. Thus, needle exchange is cost saving and life saving at
FIGURE 1. One-way Sensitivity Analysis on NSE-Program Efficacy. The
Figure on the Left Shows Costs and Cost-Savings at Various Levels of
HIV Seroprevalence Reduction. The Figure on the Right Shows QALY
Gains at Various Levels of Seroprevalence Reduction
















NSE 63,027 1,312 20.57 0.01 3,064 –
NO NSE 64,339 – 20.56 – 3,129 (Domi-
nated)
Note: Because the NSE produced cost-savings, it is the dominant strategy, and an
incremental cost-effectiveness ratio is not computed.
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values less than one-seventh the early estimate obtained from an
ecological study.
A one-way sensitivity analysis conducted on s, using the NYC-
DOMH’s low and high estimates of HIV seroprevalence among
IDUs in New York City, shows the cost-savings associated with the
NSE to have a direct linear relationship with s. Although the NSE
continues to be cost saving across all values of s, as s decreases, the
cost savings also decrease. The NSE strategy therefore remains domi-
nant over the plausible values of HIV seroprevalence in the IDU
population, and of the reduction in HIV seroprevalence associated
with NSE.
DISCUSSION
The LESHRC needle exchange program appears to save both
money and lives from both the government and societal perspectives.
From the governmental perspective, NSE results in a savings of
$1,300–$3,000 per client. From the societal perspective, NSE pro-
duces a net gain of 0.01–0.02 QALYs and averts 0.004–0.007 cases
of HIV per client per year.
However, this prediction is contingent on the extent to which the
reduction in HIV seroprevalence associated with the NSE was
accurately predicted by a single ecological study conducted before
the introduction of protease inhibitors into the medical marketplace.
Protease inhibitors, which became available at the end of 1995,
are now a standard part of HIV treatment (Wynn et al., 2004).
Because protease inhibitors act to reduce the amount of HIV virus
in the blood, the rate of transmission via shared-syringe use is likely
significantly lower compared to what it was during time frame of
Hurley et al.’s study (1997), and the reduction in HIV seroprevalence
associated with NSE would in effect be lower.
While it is difficult to estimate how much lower infection rates
might be, there are a number of reasons to suspect that NSE may
be cost saving. First, not all IDUs are receiving protease inhibitors.
Second, NSE remains cost-effective even if the actual reduction in
seroprevalence among IDUs is 0.008—about one-fourth the value
estimated by Des Jarlais et al. (2005), and one-seventh the value esti-
mated by Hurley et al. (1997). Third, the seropositive estimates of
0.029 and 0.058 reflect overall seroprevalence reduction in the general
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IDU population. Analyses specific to the population within a NSE
program would likely be substantially higher since only a fraction
of IDUs in a given geographic location actually have access to
NSE. Fourth, we excluded important cost-savings associated with
NSE, such as the possible reduction of Hepatitis B and Hepatitis C
transmission. Fifth, the costs associated with NSE used for this study,
$502 per client per year, were obtained from a New York City NSE,
where the costs of operation are likely higher than in most other parts
of the country.
This study has a number of limitations. Foremost, there is no good
estimate of NSE efficacy. Our analysis found that NSE was cost-
effective even when efficacy was one-seventh of the value from a
small-area analysis and one-fourth that of a longitudinal study
design. Nonetheless, small-area analyses may be confounded by a
number of unforeseen ecological confounders, such as program
implementation in areas where people are generally receptive to
health education programs. Likewise, longitudinal studies are poten-
tially confounded by temporal effects, such as the drop in HIV inci-
dence seen in the United States over time (though incidence outside of
the study population was considered in deriving the estimate of NSE
efficacy). While such studies find a strong correlation between the
number of needles distributed and dropping incidence of HIV=AIDS,
AIDS, both can be correlated with other factors. For instance,
advances in HIV=AIDS treatments also lower blood levels of HIV
virus, and therefore lower transmission rates. One other limitation
was our reliance upon modeled data for QALY estimation (Paltiel
et al., 2005). This model, while developed by some of the nations’
leading HIV=AIDS and modeling experts using the best available
data, relies on a number of assumptions that may bias its outputs.
Model input error was limited by biasing the study against the
conclusion that NSE is cost saving as described above.
Needle and syringe exchange is an effective HIV prevention inter-
vention that can also be a cost saving to Medicaid, as seen by the
cases of HIV averted by the Lower East Side Harm Reduction Center
in 2005. This finding is pertinent to social service providers, as it can
inform the development of a community-level strategy to prevent
HIV=AIDS and the decision to devote resources to a NSE program.
Needle and syringe exchange programs (mobile or stationary) can
also serve as a point of delivery for multiple social services including
those directly related to HIV=AIDS prevention (such as behavioral
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and biomedical prevention interventions and referral to care and
treatment) and also more general services (such as mental health
counseling, general health services, life-skills training, job-assistance,
and legal services).
Needle and syringe exchange continues to be a controversial
intervention, however, and faces opposition in the United States.
While states can legalize NSE programs, they cannot receive federal
funding. More comprehensive and up-to-date evaluation of NSE
programs would provide evidence of the full benefits of this inter-
vention strategy and will assist these programs in gaining wider
acceptance, more funding, and greater capacity.
Nonetheless, this study uses conservative estimates of the efficacy
of NSE programs and still produces cost-savings and QALY gains.
Policy makers can therefore be reasonably certain that such programs
will save lives and money. Because most medical interventions—even
most prevention programs—are associated with some net cost, this
study suggests that NSE programs should be prioritized for funding.
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